as of 12-04-2025 4:00pm EST
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 1.3B | IPO Year: | 2018 |
| Target Price: | $10.00 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.14 - $10.08 | Next Earning Date: | 11-06-2025 |
| Revenue: | $266,137,000 | Revenue Growth: | 42.05% |
| Revenue Growth (this year): | 43.89% | Revenue Growth (next year): | 20.40% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
See Remarks
Avg Cost/Share
$7.01
Shares
16,667
Total Value
$116,780.67
Owned After
1,320,176
SEC Form 4
See Remarks
Avg Cost/Share
$7.46
Shares
23,242
Total Value
$173,401.59
Owned After
2,643,153
SEC Form 4
See Remarks
Avg Cost/Share
$7.40
Shares
16,667
Total Value
$123,295.80
Owned After
1,320,176
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hecht Beth | XERS | See Remarks | Dec 1, 2025 | Sell | $7.01 | 16,667 | $116,780.67 | 1,320,176 | |
| Shannon John Patrick Jr | XERS | See Remarks | Nov 13, 2025 | Sell | $7.46 | 23,242 | $173,401.59 | 2,643,153 | |
| Hecht Beth | XERS | See Remarks | Nov 11, 2025 | Sell | $7.40 | 16,667 | $123,295.80 | 1,320,176 |
See how XERS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "XERS Xeris Biopharma Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.